Savara shares fall 20% as FDA says it will miss Molgramostim review deadline
Savara (SVRA) shares dropped 20% after the FDA missed its review deadline for molgramostim, a treatment for autoimmune pulmonary alveolar proteinosis. The FDA did not provide a revised date or explain the delay, creating uncertainty for investors. Savara is a clinical-stage biotech company focused on rare respiratory diseases.
How this was made
The 30-second read
Why it matters
The missed deadline introduces regulatory uncertainty, prompting a sell‑off.
Market read
The news directly caused a 20% intraday decline in SVRA, highlighting immediate market impact.
What to watch
The company may have received a complete response from the FDA that could shorten the remaining review time.
Background
Savara is a clinical‑stage biotech focused on rare respiratory diseases; molgramostim is its lead candidate for autoimmune PAP.
Ticker impact
FDA missed the PDUFA deadline for Savara's molgramostim, causing a ~20% share drop.
likely pressure as investors price in regulatory delay
The delay adds uncertainty to approval timing and commercial launch, reducing near‑term upside.
Market effects
Potentially dampens sentiment for rare‑disease biotech peers awaiting FDA decisions.
Limited to US biotech sector.
Low; impact confined to Savara and similar small‑cap biotech stocks.
Counterpoint
If the FDA ultimately grants approval, the stock could rebound sharply on the upside.
Key entities
- CompanySavara
Biotech developer of molgramostim.
- RegulatorFDA
U.S. agency reviewing the biologics license application.


